SusPharma - Merging Sustainable and Digital Chemical Technologies for the Development of Greener-by-Design Pharmaceuticals

安全和绿色设计是上市前的设计方法，通过这种方法，产品设计的目标是尽量减少危险化学品的使用，减少温室气体排放，促进循环经济中材料的再利用和再循环。SUSPHARMA符合欧洲对现代工业可持续发展的需求，并将在行动中发展更环保的分子制备途径，例如治疗和诊断。突破性创新将涉及：-使用可再生（生物基）碳作为药物合成的支架和基序的构建块；- C-X键形成的更清洁的合成方法（即碳氢官能化以获得C-C， C-F和C-I键形成）；-开发新的台式连续净化方法，以去除杂质和回收合成溶剂；-整合数字化方法。- LCA和TEA评估，以合理减少药品生产的影响。因此，该项目将受益于一个跨学科领域，涉及：-生物质转化用于药物合成的最新进展；-多相催化的新进展；-尖端的流动化学技术（包括合成和纯化）；-自动化和机器学习。为了应对绿色和数字化转型的挑战，以及健康技术和产品的合理供应，SUSPHARMA将专注于研究和创新活动，旨在整合五个突破性概念：CAT-to-PHARMA、WASTE-to-PHARMA、FLOW-to-PHARMA、PUR-to-PHARMA和digital - To -PHARMA。这将为制药业、研究人员和创新者带来直接的结果，促使他们开发和生产更环保的药品，这些药品要么在设计上更环保，本质上对环境的危害更小，要么使用更环保、经济上更可持续的制造工艺和技术。

Safe-and green-by-design are pre-market design approaches whereby the objectives of minimizing the use of hazardous chemicals, reducing greenhouse gas emissions, and fostering the reuse and recycling of materials in a circular economy are built into product design. SUSPHARMA fits the European need for sustainable development in modern industry and will develop during the action greener routes to prepare molecules, such as therapeutics and diagnostics. The breakthrough innovation will involve: - use of renewable (bio-based) carbon for the building block of scaffolds and motifs for drug synthesis; - cleaner synthetic methodologies for C-X bond formation (that is, C-H functionalization to obtain C-C, C-F, and C-I bond formation); - development of new benchtop continuous purification methods, to remove impurity and recycle synthetic solvents; - integration of digitalization methods. - LCA and TEA assessment for sensibly reducing the impact of pharmaceutical production. The project will thus benefit from an interdisciplinary domain, involving: - recent advances in biomass conversion for drug synthesis; - new developments in heterogeneous catalysis; - cutting-edge flow chemistry technologies (including synthesis and purification); - automation and machine learning. To address the challenge of green and digital transition and proper supply of health technologies and products, SUSPHARMA will focus on research and innovation activities that aim at integrating five breakthrough concepts: CAT-to-PHARMA, WASTE-to-PHARMA, FLOW-to-PHARMA, PUR-to-PHARMA, and DIGITAL to PHARMA. This will deliver results that are directed to pharmaceutical industries, researchers, and innovators, prompting them to develop and produce greener pharmaceuticals that are either greener by design, intrinsically less harmful for the environment, or use greener and economically more sustainable manufacturing processes and technologies.